Diabetic Medication denials in California external review
In the California DMHC record, independent physician reviewers decided 288 published external-review cases involving Diabetic Medicationand overturned the plan’s denial in 74.7%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Conditions behind Diabetic Medication denials
| Category | Decisions | Overturned |
|---|---|---|
| Diabetes | 244 | 75.8% |
| Type 2 Diabetes | 10 | 80% |
| Obesity | 5 | 80% |
| Hormone Abnormality | 4 | 75% |
| Hypertension | 3 | 66.7% |
| Ovarian Cyst | 3 | 66.7% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 267 | 76.8% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 21 | 47.6% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Ozempic. Obesity is defined as having a body mass index (BMI) over 30 kg/m2 and is associated with an increased risk of diabetes, hypertension, hyperlipidemia, stroke, and malignant tumors. Obesity is a chronic disease for which medication-assisted weight loss is indicated in conjunction with lifestyle therapy for patients who are at risk for developing type 2 diabetes mellitus. The STEP 8 clinical trial compared the efficacy and safety profile of semaglutide versus liraglutide for the treatment of patients with overweight or obesity. The authors found that semaglutide resulted in significantly greater weight loss than liraglutide and greater improvements in several cardiometabolic risk factors.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for G-Voke HypoPen. In this case, the patient has insulin-dependent diabetes complicated by gastroparesis, a delay in gastric emptying without any obstruction in the gastric outlet. It is caused by autonomic neuropathy and is often associated with an increased risk of hypoglycemia in diabetic patients. A researcher explains, “Hypoglycemia is a common problem in patients with diabetes, and often limits those trying to achieve tight glucose control. Achieving optimal glucose control is necessary to prevent microvascular complications. Hypoglycemia can cause mild disturbances to daily life, but in severe cases can be fatal.” To prevent medical sequelae of severe hypoglycemic emergencies, prompt and reliable rescue intervention is critically important.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Rybelsus tablet 14 mg. Prediabetes is a precursor to type 2 diabetes, a disease highly associated with microvascular and macrovascular disease. Patients with prediabetes have a higher average sugar than normal but not as high as those with diabetes. For patients with prediabetes, the American Association of Clinical Endocrinology (AACE) recommends lifestyle changes. Medications for obesity are recommended for patients with a body mass index (BMI) over 27 kg/m2 such as phentermine/topiramate ER, liraglutide, or weekly semaglutide.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Mounjaro. Diabetes mellitus is a common, albeit potentially devastating, medical condition that has increased in prevalence over the past few decades to constitute a major public health challenge in the twenty-first century. The mortality rate for patients with diabetes is one and a half times higher than for individuals without diabetes. Tirzepatide (brand name Mounjaro), a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus, along with diet and exercise, based on clinical data demonstrating that tirzepatide is superior to placebo in improving hemoglobin (Hb) A1C levels.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Diabetic Medication, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY